Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study
Per Soelberg Sørensen, Luigi Pontieri, Hanna Joensen, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 70, pp. 104491-104491
Open Access | Times Cited: 23

Showing 23 citing articles:

Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing–remitting multiple sclerosis patients: a monocentric longitudinal observational study
Chiara Zanetta, Maria A. Rocca, Alessandro Meani, et al.
Journal of Neurology (2023) Vol. 270, Iss. 7, pp. 3553-3564
Open Access | Times Cited: 18
Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review
Óscar Fernández, Per Soelberg Sørensen, Gıancarlo Comı, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis
Rosa Cortese, Giovanna Testa, Francesco Assogna, et al.
CNS Drugs (2024) Vol. 38, Iss. 4, pp. 267-279
Open Access | Times Cited: 4
Administration and Monitoring Burden of High-Efficacy Disease-Modifying Therapies for Multiple Sclerosis: A Delphi Consensus of Clinical Experts from Saudi Arabia
Seraj Makkawi, Ahmad Abulaban, Yaser Al Malik, et al.
Neurology and Therapy (2025)
Open Access
Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study
Tjalf Ziemssen, Ann Bass, Bart Van Wijmeersch, et al.
Therapeutic Advances in Neurological Disorders (2025) Vol. 18
Open Access
CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis
Damiano Marastoni, Matteo Foschi, Chiara Eccher, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Evaluation of therapy satisfaction with cladribine tablets in patients with RMS: Final results of the non-interventional study CLEVER
Tjalf Ziemssen, Anita Posevitz‐Fejfár, Anita Chudecka, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 90, pp. 105812-105812
Open Access | Times Cited: 2
Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort
Sofie Aerts, Hamza Khan, Deborah Severijns, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 75, pp. 104735-104735
Closed Access | Times Cited: 6
Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States
Yan Song, Yan Wang, Schiffon L. Wong, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 79, pp. 105052-105052
Open Access | Times Cited: 4
Holistic, Long-Term Management of People with Relapsing Multiple Sclerosis with Cladribine Tablets: Expert Opinion from France
Jonathan Ciron, Bertrand Bourre, Giovanni Castelnovo, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 3, pp. 503-518
Open Access | Times Cited: 1
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop)
Irene Schiavetti, Alessio Signori, Angela Albanese, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 6
Open Access | Times Cited: 1
Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy
Massimo Filippi, Laura Ferrè, Chiara Zanetta, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 1
Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing
Alessia Manni, Florian Oggiano, C. Palazzo, et al.
Journal of the Neurological Sciences (2024) Vol. 462, pp. 123070-123070
Open Access | Times Cited: 1
Safety of high efficacy therapies in older people with Multiple Sclerosis: a real-world evidence study
Berenice Silva, Federico Casales, Claudia Burbano Donoso, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 90, pp. 105830-105830
Closed Access | Times Cited: 1
The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis
Helmut Butzkueven, Jan Hillert, Merja Soilu‐Hänninen, et al.
Current Medical Research and Opinion (2023) Vol. 39, Iss. 10, pp. 1367-1374
Open Access | Times Cited: 3
Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis
Daniela Rau, Beate S. Müller, Susanne Übler
Advances in Therapy (2023) Vol. 40, Iss. 12, pp. 5547-5556
Open Access | Times Cited: 2
Multiple Sclerosis: Immune Cells, Histopathology, and Therapeutics
Manisha S. Patil, Linda Yingqi Lin, Felix Marsh‐Wakefield, et al.
Sclerosis (2024) Vol. 2, Iss. 3, pp. 117-139
Open Access
Complementary strategies to be used in conjunction with animal models for multiple sclerosis drug discovery: adapting preclinical validation of drug candidates to the need of remyelinating strategies
Imane Charmarké-Askar, Caroline Spenlé, Dominique Bagnard
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 9, pp. 1115-1124
Closed Access
Real-world effectiveness of cladribine as an escalation strategy for MS: Insights from the Czech nationwide ReMuS registry
Pavel Potužník, Jiří Drahota, Dana Horáková, et al.
Journal of Central Nervous System Disease (2024) Vol. 16
Open Access
Early clinical effect of cladribine in patients with highly active multiple sclerosis in Mexico
Sergio Sauri-Suárez, Sandra Quiñones, Manuel de la Maza-Flores, et al.
Multiple Sclerosis Journal - Experimental Translational and Clinical (2024) Vol. 10, Iss. 3
Open Access
Experience with the use of cladribine tablets in real-life clinical practice: independent analysis of data from 12 Russian clinical centres
Alexey Boyко, В. М. Алифирова, D. V. Pashkovskaya, et al.
Neurology neuropsychiatry Psychosomatics (2024) Vol. 16, pp. 44-50
Open Access
Cladribine use trend in Latin America: the changes in patient profile impact in the drug effectiveness
Berenice Silva, Alejandra Heriz, Jeremías Ayerbe, et al.
Neurological Sciences (2024)
Closed Access
Identification of alemtuzumab-suitable multiple sclerosis patients in Slovakia and sequencing of post-alemtuzumab immunomodulatory treatment
Ema Kantorová, Marianna Vítková, Martina Martiníková, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access
Page 1

Scroll to top